This is a competitive renewal application for the Cancer Center Support Grant of Roswell Park Cancer Institute (RPCI). an NCI-designated Comprehensive Cancer Center, for the grant period 1985 - 2000. Under the leadership of Institute President and CEO, Thomas B. Tomasi, M.D., Ph.D, this grant is entering its 20th year of uninterrupted funding. Over the past two decades, the CCSG has provided indispensable support to the research programs of RPCI. The present CCSG application reflects the significant evolution and progress of RPCIs research programs with the inclusion of 6 mature programs, 2 developing programs and 12 shared resources, seven of which are new or significantly expanded resources carried over from the merger of the Institute Core Grant with the Grace Cancer Drug Center Core Grant. Since the last CCSG renewal, there have been numerous changes in the RPCI research programs including recruitment of new senior faculty, scientific and clinical departments have been reorganized, major capital investments and the commitment of New York State to design and build a new research laboratory, vivarium, nursing tower, ambulatory clinic and diagnostic and treatment facility, all in addition to major renovations to existing research facilities. The CCSG plays a central role in the planning and evaluation, support and administration of Roswell's basic and clinical research programs. With the renewal of this CCSG, combined with the commitment of New York State to support the cancer mission of Roswell Park and its highly dedicated research faculty, Roswell Park will be poised to enter the next century as one of the nations leading cancer centers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Wintrob, Zachary A P; Hammel, Jeffrey P; Nimako, George K et al. (2017) Insulin use, hormone receptor status and hematopoietic cytokines? circulation in women with diabetes mellitus and breast cancer. Data Brief 11:382-390
Murphy, Maureen E; Liu, Song; Yao, Song et al. (2017) A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer 3:5
Liu, Song; Kumari, Sangeeta; Hu, Qiang et al. (2017) A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife 6:
Espinal, Allyson C; Buas, Matthew F; Wang, Dan et al. (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166:559-568
Danaher, Patrick; Warren, Sarah; Dennis, Lucas et al. (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18
Oakley, Emily; Bellnier, David A; Hutson, Alan et al. (2017) Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 49:599-608
Gage-Bouchard, Elizabeth A (2017) Social support, flexible resources, and health care navigation. Soc Sci Med 190:111-118
Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Ho, Christine M; McCarthy, Philip L; Wallace, Paul K et al. (2017) Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv 1:1056-1066

Showing the most recent 10 out of 1391 publications